Goldman Sachs
PHAT icon

Goldman Sachs’s Phathom Pharmaceuticals PHAT Stock Holding History

Goldman Sachs’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
1,778,032
+1,151,836
+184% +$13.1M ﹤0.01% 2670
2026
Q1 		$6.96M Buy
626,196
+234,151
+60% +$2.96M ﹤0.01% 3373
2025
Q4 		$6.5M Buy
392,045
+240,013
+158% +$3.43M ﹤0.01% 3508
2025
Q3 		$1.79M Sell
152,032
-40,494
-21% -$418K ﹤0.01% 4581
2025
Q2 		$1.85M Buy
192,526
+4,652
+2% +$25.7K ﹤0.01% 4245
2025
Q1 		$1.18M Sell
187,874
-224,388
-54% -$1.36M ﹤0.01% 4552
2024
Q4 		$3.35M Sell
412,262
-21,959
-5% -$272K ﹤0.01% 3836
2024
Q3 		$7.85M Buy
434,221
+16,937
+4% +$237K ﹤0.01% 2940
2024
Q2 		$4.3M Buy
417,284
+209,912
+101% +$2.16M ﹤0.01% 3296
2024
Q1 		$2.2M Sell
207,372
-2,839
-1% -$24.1K ﹤0.01% 3800
2023
Q4 		$1.92M Buy
210,211
+71,711
+52% +$618K ﹤0.01% 3955
2023
Q3 		$1.44M Sell
138,500
-16,168
-10% -$222K ﹤0.01% 4012
2023
Q2 		$2.21M Buy
154,668
+105,987
+218% +$1.22M ﹤0.01% 3801
2023
Q1 		$348K Sell
48,681
-25,331
-34% -$223K ﹤0.01% 5033
2022
Q4 		$830K Buy
74,012
+16,670
+29% +$172K ﹤0.01% 4546
2022
Q3 		$635K Buy
57,342
+4,970
+9% +$47.4K ﹤0.01% 4813
2022
Q2 		$442K Buy
52,372
+24,035
+85% +$247K ﹤0.01% 5170
2022
Q1 		$386K Sell
28,337
-5,780
-17% -$93.4K ﹤0.01% 5504
2021
Q4 		$671K Buy
34,117
+26,954
+376% +$634K ﹤0.01% 5160
2021
Q3 		$230K Buy
+7,163
New +$238K ﹤0.01% 5656
2021
Q1 		– Sell
-44,078
Closed -$1.46M – 6279
2020
Q4 		$1.46M Buy
+44,078
New +$1.79M ﹤0.01% 3946
2020
Q1 		– Sell
-6,492
Closed -$202K – 5478
2019
Q4 		$202K Buy
+6,492
New +$163K ﹤0.01% 4892

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Goldman Sachs's PHAT Position: Q2 2026 in Review

Goldman Sachs increased its Phathom Pharmaceuticals (PHAT) stake by 184% in Q2 2026, buying an estimated $13.1M and bringing the position to 1,778,032 shares worth $19.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2670.

Goldman Sachs first reported a position in PHAT in Q4 2019 and has held it in 22 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Goldman Sachs held 1,778,032 shares of Phathom Pharmaceuticals worth $19.3M as of Q2 2026.
  • Goldman Sachs bought 1,151,836 Phathom Pharmaceuticals shares in Q2 2026, an estimated $13.1M.
  • Phathom Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2670 holding.
  • Goldman Sachs first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.